Crisis: An Open Forum Webinar Series for Pharmacists May 21, 2020 - - PowerPoint PPT Presentation

American Pharmacists Association

Addressing the COVID-19 Crisis: An Open Forum Webinar Series for Pharmacists

May 21, 2020

American Pharmacists Association

Michael D. Hogue, PharmD, FAPHA, FNAP Dean and Professor Loma Linda University School of Pharmacy President, APhA Host and Moderator

American Pharmacists Association

Today’s Focus: Discuss antibody testing, how to evaluate antibody tests, and implications for pharmacists.

American Pharmacists Association

Paul C. Herrmann, MD, PhD Professor and Chair Department of Pathology and Human Anatomy Loma Linda University School of Medicine Guest Speaker

American Pharmacists Association

Daniel Zlott, PharmD, BCOP Vice President Professional Education Resources American Pharmacists Association Guest Speaker

American Pharmacists Association

Ilisa BG Bernstein, PharmD, JD, FAPhA Senior Vice President, Pharmacy Practice and Government Affairs American Pharmacists Association Subject Matter Expert: : Q&A

American Pharmacists Association

Format for Today’s Webinar

1:00 pm: Introductions 1:05 pm: Presentation by Dr. Daniel Zlott, Vice President, Professional Education Resources, American Pharmacists Association 1:15 pm: Presentation by Dr. Paul Herrmann, Professor and Chair for the Department of Pathology and Human Anatomy, Loma Linda University School of Medicine 1:25 pm: Open Forum: A Minute for Your Thoughts 1:50 pm: Wrap Up: Review of APhA’s Ongoing Activities and What’s Coming

American Pharmacists Association

Presentation by Dr. Daniel Zlott An overview of COVID-19 infection and the immune response

American Pharmacists Association

Overv rview of COVID-19 Vir irus

• COVID-19 is caused by the Severe Acute Respiratory

Syndrome Coronavirus 2 (SARS-CoV-2) – for the sake

• f simplicity, we’ll call it the COVID-19 virus
• The COVID-19 virus is an enveloped RNA virus
• The COVID-19 virus consists of1
• Spike proteins (S protein)
• Envelope (lipid membrane)
• Envelope (E) and Membrane (M) proteins
• Nucleocapsid
• Nucleoproteins (N protein)
• Genetic material (RNA)
• Miscellaneous proteins
• Non-structural proteins (nsp)
• Accessory proteins (ORF, and others)

3D Printed Model of COVID-19; Image Credit: NIAID-RML

• 1. Mousavizadeh, et al. J Microbiol Immunol Infect. 2020; DOI: https://doi.org/10.1016/j.jmii.2020.03.022

American Pharmacists Association

COVID-19 Antigens

Scanning electron migrograph of SARS-CoV-2; Image Credit: NIAID-RML

• There are a number of potential epitopes that

have been confirmed or are hypothesized to generate an immune response1,2:

• S protein
• N protein
• M protein
• Nsp3, nsp4
• ORF3a, ORF8
• These epitopes have been confirmed or

hypothesized to generate both T- and B-cell responses1,2

• For the purposes of today’s discussion, we will be

focusing on B-Cell responses

• 1. Grifoni, et al. Cell Host & Microbe. 2020; DOI: https://doi.org/10.1016/j.chom.2020.03.002
• 2. Grifoni, et al. Cell. 2020; DOI: https://doi.org/10.1016/j.cell.2020.05.015

American Pharmacists Association

General Review of Antibody Development

Understanding antibody development1:

• Antibodies are produced by activated B-cells (also

called plasma cells)

• B-lymphocytes recognize their targets through

immunoglobulins present on the cell surface (B-cell receptor)

• Once a B-lymphocyte recognizes its target, it must

also be activated by CD4+ T-cells (helper T-cells), which secrete B-lymphocyte growth factors

• Activated B-cells become plasma cells or memory

B-cells

• Each plasma cell makes a single type of antibody
• There are 5 general classes of antibody

(immunoglobulins)

• IgA
• IgD
• IgE
• IgM
• IgG
• 1. Zlott, et al. ‘Function and Evaluation of the Immune System’, in Dipiro, et al. Pharmacotherapy: A Pathophysiologic Approach, 11th Ed. McGraw Hill, 2019

American Pharmacists Association

General Review of Antibody Development

• Understanding antibody development1:
• It takes time to develop an antibody response
• nce exposed to antigen1
• IgM: Initial antibody produced upon initial

exposure to antigen

• IgM appears 4-7 days after initial exposure, and

peaks 7-10 days after initial exposure

• IgG: Longer term antibody produced upon initial

exposure – provides long term protection against pathogen

• IgG appears 7-10 days after initial exposure, and

peaks 10-14 days after initial exposure

• Upon re-exposure, memory B-cells rapidly

reactivate plasma cells, which produce IgG, neutralizing pathogen

• 1. Zlott, et al. ‘Function and Evaluation of the Immune System’, in Dipiro, et al. Pharmacotherapy: A Pathophysiologic Approach, 11th Ed. McGraw Hill, 2019
• 2. Guzman, et al. Nature Reviews Microbiology 2010;8:S7-S16.

Image: Immunoglobulin response curve upon exposure to Dengue Fever.2

American Pharmacists Association

Do People Generate an Antibody Response to COVID-19? 19?

• Yes!
• A cross-sectional study from 3 hospitals

which included 285 pts demonstrated that 100% of pts develop either IgM, IgG, or both within 19 days of symptom

• nset
• All pts were confirmed to be COVID-19+ by

PCR

• Serum Ig levels tested by ELISA
• 1. Long, et al. Nature Medicine. 2020; DOI: https://doi.org/10.1038/s41591-020-0897-1

Figure 1a from Long, et al.1

American Pharmacists Association

Presentation by Dr. Paul Herrmann An overview of how antibody testing works and considerations for pharmacists

American Pharmacists Association

Enzyme-Linked Im Immunosorbent Assay (E (ELISA)

socratic.org

American Pharmacists Association

antibioticresearch.org.uk

Lateral Flo low Test

American Pharmacists Association

In Instrument Validation

Must Demonstrate:

• Precision
• Accuracy
• Reproducibility
• Limits of Detection/Range
• Correlation to Existing Method
• Relevant Reference Range

American Pharmacists Association

American Pharmacists Association

COVID-19 IgM/IgG Testing within 5 days of Positive PCR COVID-19 IgM/IgG Testing within 14 Days of Positive PCR

American Pharmacists Association

Unusual Regulatory ry Climate

• Ordinarily a test is developed by a company. Then the FDA

evaluates and approves it after extensive testing. Clinical labs do a quick validation to make sure everything is working correctly on site.

• Due to current situation, FDA issued Emergency Use Authorization

(EUA). High complexity CLIA certified labs just inherited all the work, liability and risk of what FDA used to do for us.

• Antibody testing was turned loose by FDA even before EUA
• issuance. Even more imperative that lab validation be performed

carefully and correctly.

American Pharmacists Association

Fin inding a Good Test

American Pharmacists Association

Tim imeline for Bri ringing in in a Lab Test

New Test Buy Install Validate Go Live Monitor

Don’t forget there will also need to be a supply chain for:

reagents and supplies for instrument specimen collection materials staff to run the test in addition to everything else they were already doing

American Pharmacists Association

My pharmacy practice site is considering offering antibody testing when it becomes available:

• A. Yes
• B. No
• C. Not applicable to my practice

Polling Question

American Pharmacists Association

• Use the Questions field on the GoToWebinar toolbar to submit comments

and questions related to the topic discussion

• Individuals whose submissions are selected will be asked by the moderator

to state the comment or question for the audience. The line for the individual will be unmuted to read their comment or question.

• To maximize the number of questions/comments addressed, a 60-second

time limit will be in effect for everyone to state their question or comment.

• We will try to get to as many comments and questions as possible. We

have created a new forum for COVID-19 discussions where further discussion post-webinar. Information on participating in this forum will be provided at the end of the open forum.

Open Forum Ground Rules

American Pharmacists Association

Open Forum Discussion: A Minute for Your Thoughts Comments, Questions, Feedback

American Pharmacists Association

Review of APhA’s Ongoing Activities and What’s Coming

American Pharmacists Association

NEW Episodes – APhA’s 15 on COVID-19

An education series designed to help you sort COVID-19 fact from fiction. Each episode is 15-20 minutes and provides CPE.

Episode 16: Anticoagulation in COVID-19 http://elearning.pharmacist.com/products/6106 /15-on-covid-19-05-14-2020-anticoagulation/ Episode 17: Antibody Development and Reinfection http://elearning.pharmacist.com/products/6110 /15-on-covid-19-05-18-2020-antibody- development-and-reinfection

American Pharmacists Association

Check out the practice resources here

• COVID-19 Fraudulent Medical Products and

Scams

• Demystifying Testing for SARS-CoV-2 Virus:

Frequently Asked Questions

• Vaccines in Development for COVID-19
• New resources weekly!

American Pharmacists Association

“…states and localities may not ‘establish, enforce, or continue in effect’ any legal requirement that prohibits or effectively prohibits licensed pharmacists from ordering and administering FDA-authorized COVID-19 tests.”

G

https://www.hhs.gov/sites/default/files/advi sory-opinion-20-02-hhs-ogc-prep-act.pdf

U.S. Health and Human Services Office of the General Counsel Advisory Opinion 20-02, May 19,2020

Pharmacist Testing

American Pharmacists Association

actioncenter.pharmacist.com

GO TO:

American Pharmacists Association

Post on ENGAGE

Pharmacy’s Response to COVID-19

POST your questions SHARE your lessons learned SUPPORT your colleagues ACCESS the latest information

How are you preparing your pharmacy and staff to offer testing? What barriers to testing are you facing?

American Pharmacists Association

• Weekly webinar will be on Thursday,

May 28th, from 1-2 pm ET

• The webinar recording and slides will

be available within 24 hours

Join Us

Same day, Same time, Same Place

https://www.pharmacist.com/coronavirus/resources-training